PI3K/AKT信号通路失调对伤口愈合有显著影响。 PI3K/AKT信号通路开启或关闭一些下游调控蛋白,包括哺乳动物雷帕霉素靶蛋白(mTOR)和糖原合酶激酶3 (GSK3)。AKT磷酸化mTOR和GSK3影响多种生物活性,如增殖、生长和生存。mTOR激活失调导致与糖尿病和心血管疾病相关的并发症,而磷酸化依赖于GSK3亚型的抑制;GSK3 β (β)...
PI3K/AKT信号通路开启或关闭一些下游调控蛋白,包括哺乳动物雷帕霉素靶蛋白(mTOR)和糖原合酶激酶3 (GSK3)。AKT磷酸化mTOR和GSK3影响多种生物活性,如增殖、生长和生存。mTOR激活失调导致与糖尿病和心血管疾病相关的并发症,而磷酸化依赖于GSK3亚型的抑制;GSK3 β (β)和GSK3 α (α)通过AKT调控包括糖原合成酶(GS...
PDK1. 仅能使 Thr308 位点磷酸化,但 Akt 的 PH 区可与脂质产物结合,形成 PDK1/PDK2复合体,从而使得 Akt 能通过 PDK2对其Ser473位点的磷酸化而被激活。活化的Akt进一步激活或抑制下游Bad、Caspase-9、NF-xB和GSK-3β等靶蛋白,调节细胞生理过程。
MF:C20H20ClN3 Structure: Chemical Name:GSK-3BETA INHIBITOR XII CAS:601514-19-6 MF:C18H14N4O2 Structure: Chemical Name:PF-05212384 CAS:1197160-78-3 MF:C32H41N9O4 Structure: Chemical Name:IPI 145 CAS:1201438-56-3 MF:C22H17ClN6O Structure: Chemical Name:OSI-027 CAS:936890-98-1 MF:C21H...
Integrin，FAK，Paxillin，ILK，PIP3，S6，p70S6K，RTK，Gab1，Gab2，IRS-1，PI3K，PTEN，AKT，PDK1，Cytokine Receptor，Jak1，CD19，BCR，Ag，BCAP，Syk，Lyn，GPCR，TSC1，TSC2，Gβγ，GαGTP，PP2A，PHLPP，CTMP，PDCD4，4E-BP1，ATG13，mTORC1，TSC1，TSC2，PRAS40，XIAP，...
(2005). Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25: 1869–1878. CAS PubMed PubMed Central Google Scholar Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA . (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in ...
PI3K/AKT/mTOR 通路是一种细胞内信号传导通路,参与多个生物学过程,例如细胞增殖、凋亡、血管生成和葡萄糖代谢1,2。细胞外生长因子与跨膜受体酪氨酸激酶(RTK),例如 EGFR3,4,结合后会激活该通路,随后磷脂酰肌醇 3-激酶(PI3K)和丝氨酸/苏氨酸蛋白激酶 B(PKB/AKT)也被激活,从而导致一系列下游底物发生丝氨酸和/或苏...
别名: AR-A014418 抑制剂;N-(4-甲氧基苄基)-N'-(5-硝基-1,3-噻唑-2-基)脲;N-(4-甲氧基苄基)-N-(5-硝基-1,3-噻唑-2-基)脲;茚草酮;GSK-3BETA 抑制剂 VIII CAS No.:487021-52-3 分子式: C12H12N4O4S 分子量: 308.31 A126821 AR-A014418,GSK-3抑制剂 ,Moligand™, ≥98%,≥98% ...
42.Georgakis GV, Younes A. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.Expert Rev Anticancer Ther. 2006;6:131-140.[PubMed] 43.Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S. Synergistic augmentation of rapamycin-induced autophagy in ...
Abnormal activation of the Akt GSK3beta signaling pathway in peripheral blood T cells from patients with systemic lupus erythematosus[J]. Cell Cycle, 2009, 8(17):2789 2793.[11]PERL A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases[J]. Nat Rev Rheumatol, 2016, ...